These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 20350875)
21. [Bacteremic pneumococcal pneumonia]. Pineda Solas V; Pérez Benito A; Domingo Puiggros M; Larramona Carrera H; Segura Porta F; Fontanals Aymerich D An Esp Pediatr; 2002 Nov; 57(5):408-13. PubMed ID: 12467543 [TBL] [Abstract][Full Text] [Related]
22. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. Klugman KP; Madhi SA; Huebner RE; Kohberger R; Mbelle N; Pierce N; N Engl J Med; 2003 Oct; 349(14):1341-8. PubMed ID: 14523142 [TBL] [Abstract][Full Text] [Related]
23. Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children. Abrão WM; Mello LM; Silva AS; Nunes AA Rev Soc Bras Med Trop; 2015; 48(1):44-9. PubMed ID: 25860463 [TBL] [Abstract][Full Text] [Related]
24. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Weil-Olivier C; Gaillat J Vaccine; 2014 Apr; 32(18):2022-6. PubMed ID: 24565755 [TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641 [TBL] [Abstract][Full Text] [Related]
26. Pneumococcal conjugate vaccines--a European perspective. Reinert RR Int J Med Microbiol; 2004 Oct; 294(5):277-94. PubMed ID: 15532987 [TBL] [Abstract][Full Text] [Related]
27. New vaccines against otitis media: projected benefits and cost-effectiveness. O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. van Santen KL; Bednarczyk RA; Adjaye-Gbewonyo D; Orenstein WA; Davis R; Omer SB Pediatr Infect Dis J; 2013 Nov; 32(11):1180-4. PubMed ID: 23856786 [TBL] [Abstract][Full Text] [Related]
29. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Esposito S; Lizioli A; Lastrico A; Begliatti E; Rognoni A; Tagliabue C; Cesati L; Carreri V; Principi N Respir Res; 2007 Feb; 8(1):12. PubMed ID: 17313667 [TBL] [Abstract][Full Text] [Related]
30. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Madhi SA; Kuwanda L; Cutland C; Klugman KP Clin Infect Dis; 2005 May; 40(10):1511-8. PubMed ID: 15844075 [TBL] [Abstract][Full Text] [Related]
31. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Li ST; Tancredi DJ Pediatrics; 2010 Jan; 125(1):26-33. PubMed ID: 19948570 [TBL] [Abstract][Full Text] [Related]
32. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399 [TBL] [Abstract][Full Text] [Related]
33. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. Ansaldi F; Sticchi L; Durando P; Carloni R; Oreste P; Vercelli M; Crovari P; Icardi G J Int Med Res; 2008; 36(6):1255-60. PubMed ID: 19094434 [TBL] [Abstract][Full Text] [Related]
34. A qualitative study on knowledge, perceptions, and attitudes of mothers and health care providers toward pneumococcal conjugate vaccine in Bandung, West Java, Indonesia. Harjaningrum AT; Kartasasmita C; Orne-Gliemann J; Jutand MA; Goujon N; Koeck JL Vaccine; 2013 Mar; 31(11):1516-22. PubMed ID: 23318150 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274 [TBL] [Abstract][Full Text] [Related]
36. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625 [TBL] [Abstract][Full Text] [Related]
37. Pneumococcal vaccines and the prevention of community-acquired pneumonia. Esposito S; Principi N Pulm Pharmacol Ther; 2015 Jun; 32():124-9. PubMed ID: 24607597 [TBL] [Abstract][Full Text] [Related]
38. [Pneumococcal disease prevention from early infancy to old age]. Mészner Z Orv Hetil; 2014 Feb; 155(7):243-7. PubMed ID: 24509352 [TBL] [Abstract][Full Text] [Related]
39. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants. Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H; Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879 [TBL] [Abstract][Full Text] [Related]
40. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. Simonsen L; Taylor RJ; Young-Xu Y; Haber M; May L; Klugman KP mBio; 2011 Jan; 2(1):e00309-10. PubMed ID: 21264063 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]